Regulation of spontaneous eosinophil apoptosis-a neglected area of importance

Journal of Cell Death

Volumn 7, Issue 1, 2014, Pages 1-9

  Ilmarinen, Pinja ^a   Moilanen, Eeva ^a   Kankaanranta, Hannu ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Asthma; Eosinophils; Fas; Glucocorticoids; Spontaneous apoptosis

Indexed keywords

APOPTOSIS INDUCING FACTOR; APOPTOSIS SIGNAL REGULATING KINASE 1; APOPTOSOME; CALPAIN; CASPASE 3; CASPASE 6; CASPASE 8; CASPASE 9; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; ENDONUCLEASE G; FAS LIGAND; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE H2AX; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 3; INTERLEUKIN 5; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; ASTHMA; CELL STRESS; DNA FRAGMENTATION; EOSINOPHIL; HUMAN; HYPOXIA; INTRACELLULAR SIGNALING; LUNG LAVAGE; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION;

EID: 84896731381     PISSN: None     EISSN: 11790660     Source Type: Journal    
DOI: 10.4137/JCD.S13588     Document Type: Article

References (135)

1. Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol. 2004; 113:30-37.
2. Trivedi SG, Lloyd CM. Eosinophils in the pathogenesis of allergic airways disease. Cell Mol Life Sci. 2007; 64:1269-1289.
3. Zuo L, Rothenberg ME. Gastrointestinal eosinophilia. Immunol Allergy Clin North Am. 2007; 27:443-455.
4. Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: current concepts and treatments. Br J Haematol. 2009; 145:271-285.
5. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens. 2007; 70:1-11.
6. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009; 360:985-993.
7. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009; 360:973-984.
8. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003; 112:1029-1036.
9. Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, et al. A critical role for eosinophils in allergic airways remodeling. Science. 2004; 305:1776-1779.
10. Park YM, Bochner BS. Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol Res. 2010; 2:87-101.
11. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012. Cell Death Differ. 2012; 19:107-120.
12. Kankaanranta H, Moilanen E, Zhang X. Pharmacological regulation of human eosinophil apoptosis. Curr Drug Targets Inflamm Allergy. 2005; 4:433-445.
13. Walsh G. Eosinophil apoptosis and clearance in asthma. J Cell Death. 2013; 6:17-25.
14. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006; 368:804-813.
15. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009; 180:388-395.
16. Farahi N, Singh NR, Heard S, Loutsios C, Summers C, Solanki CK, et al. Use of 111-indium-labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects. Blood. 2012; 120:4068-4071.
17. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev. 1999; 51:213-340.
18. Lukawska JJ, Livieratos L, Sawyer BM, Lee T, O'Doherty M, Blower PJ, et al. Real-time differential tracking of human neutrophil and eosinophil migration in vivo. J Allergy Clin Immunol. 2014; 133:233-239.
19. Canonico B, Betti M, Luchetti F, Battistelli M, Falcieri E, Ferri P, et al. Flow cytometric profiles, biomolecular and morphological aspects of transfixed leukocytes and red cells. Cytometry B Clin Cytom. 2010; 78:267-278.
20. Zimmermann N, McBride ML, Yamada Y, Hudson SA, Jones C, Cromie KD, et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy. 2008; 63:1156-1163.
21. Zhang X, Moilanen E, Kankaanranta H. Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol. 2000; 406:325-332.
22. Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002; 71:1523-1534.
23. Lamas AM, Leon OG, Schleimer RP. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. J Immunol. 1991; 147:254-259.
24. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol. 1991; 147:3490-3495.
25. Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med. 2000; 161:1881-1886.
26. Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest. 1997; 100:1677-1684.
27. Matsumoto K., Terakawa M., Miura K., Fukuda S., Nakajima T., Saito H. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol. 2004; 172:2186-2193.
28. Woolley KL, Gibson PG, Carty K, Wilson AJ, Twaddell SH, Woolley MJ. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med. 1996; 154:237-243.
29. Druilhe A, Wallaert B, Tsicopoulos A, Lapa e Silva JR, Tillie-Leblond I, Tonnel AB, et al. Apoptosis, proliferation, and expression of Bcl-2, Fas, and Fas ligand in bronchial biopsies from asthmatics. Am J Respir Cell Mol Biol. 1998; 19: 747-757.
30. Vignola AM, Chanez P, Chiappara G, Siena L, Merendino A, Reina C, et al. Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol. 1999; 103:563-573.
31. Duncan CJ, Lawrie A, Blaylock MG, Douglas JG, Walsh GM. Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. Eur Respir J. 2003; 22:484-490.
32. Gochuico BR, Miranda KM, Hessel EM, De Bie JJ, Van Oosterhout AJ, Cruikshank WW, et al. Airway epithelial Fas ligand expression: potential role in modulating bronchial inflammation. Am J Physiol. 1998; 274:L444-L449.
33. Solarewicz-Madejek K, Basinski TM, Crameri R, Akdis M, Akkaya A, Blaser K, et al. T cells and eosinophils in bronchial smooth muscle cell death in asthma. Clin Exp Allergy. 2009; 39:845-855.
34. Darveau ME, Jacques E, Rouabhia M, Hamid Q, Chakir J. Increased T-cell survival by structural bronchial cells derived from asthmatic subjects cultured in an engineered human mucosa. J Allergy Clin Immunol. 2008; 121:692-699.
35. Spinozzi F, Agea E, Fizzotti M, Bassotti G, Russano A, Droetto S, et al. Role of T-helper type 2 cytokines in down-modulation of Fas mRNA and receptor on the surface of activated CD4(+) T cells: molecular basis for the persistence of the allergic immune response. FASEB J. 1998; 12:1747-1753.
36. Sharma SK, Almeida FA, Kierstein S, Hortobagyi L, Lin T, Larkin A, et al. Systemic FasL neutralization increases eosinophilic inflammation in a mouse model of asthma. Allergy. 2012; 67:328-335.
37. Uller L, Rydell-Tormanen K, Persson CG, Erjefalt JS. Anti-Fas mAb-induced apoptosis and cytolysis of airway tissue eosinophils aggravates rather than resolves established inflammation. Respir Res. 2005; 6:90.
38. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992; 326:298-304.
39. Park CS, Choi YS, Ki SY, Moon SH, Jeong SW, Uh ST, et al. Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways. Eur Respir J. 1998; 12:872-878.
40. Adachi T, Motojima S, Hirata A, Fukuda T, Makino S. Eosinophil viabilityenhancing activity in sputum from patients with bronchial asthma, contributions of interleukin-5 and granulocyte/macrophage colony-stimulating factor. Am J Respir Crit Care Med. 1995; 151:618-623.
41. Tai PC, Sun L, Spry CJ. Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol. 1991; 85:312-316.
42. van der Bruggen T, Caldenhoven E, Kanters D, Coffer P, Raaijmakers JA, Lammers JW, et al. Interleukin-5 signaling in human eosinophils involves JAK2 tyrosine kinase and Stat1 alpha. Blood. 1995; 85:1442-1448.
43. Yousefi S, Hoessli DC, Blaser K, Mills GB, Simon HU. Requirement of lyn and syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med. 1996; 183:1407-1414.
44. Pazdrak K, Olszewska-Pazdrak B, Stafford S, Garofalo RP, Alam R. Lyn, Jak2, and raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only raf-1 kinase is essential for eosinophil activation and degranulation. J Exp Med. 1998; 188:421-429.
45. Rosas M, Dijkers PF, Lindemans CL, Lammers JW, Koenderman L, Coffer PJ. IL-5-mediated eosinophil survival requires inhibition of GSK-3 and correlates with beta-catenin relocalization. J Leukoc Biol. 2006; 80:186-195.
46. Pazdrak K, Schreiber D, Forsythe P, Justement L, Alam R. The intracellular signal transduction mechanism of interleukin 5 in eosinophils: the involvement of lyn tyrosine kinase and the ras-raf-1-MEK-microtubule-associated protein kinase pathway. J Exp Med. 1995; 181:1827-1834.
47. Pazdrak K, Stafford S, Alam R. The activation of the jak-STAT 1 signaling pathway by IL-5 in eosinophils. J Immunol. 1995; 155:397-402.
48. Coffer PJ, Schweizer RC, Dubois GR, Maikoe T, Lammers JW, Koenderman L. Analysis of signal transduction pathways in human eosinophils activated by chemoattractants and the T-helper 2-derived cytokines interleukin-4 and interleukin- 5. Blood. 1998; 91:2547-2557.
49. Shen ZJ, Esnault S, Schinzel A, Borner C, Malter JS. The peptidyl-prolyl isomerase Pin1 facilitates cytokine-induced survival of eosinophils by suppressing Bax activation. Nat Immunol. 2009; 10:257-265.
50. Kankaanranta H, De Souza PM, Barnes PJ, Salmon M, Giembycz MA, Lindsay MA. SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther. 1999; 290:621-628.
51. Miike S, Nakao A, Hiraguri M, Kurasawa K, Saito Y, Iwamoto I. Involvement of JAK2, but not PI 3-kinase/Akt and MAP kinase pathways, in antiapoptotic signals of GM-CSF in human eosinophils. J Leukoc Biol. 1999; 65: 700-706.
52. Dewson G, Cohen GM, Wardlaw AJ. Interleukin-5 inhibits translocation of Bax to the mitochondria, cytochrome c release, and activation of caspases in human eosinophils. Blood. 2001; 98:2239-2247.
53. Alam R, Forsythe P, Stafford S, Fukuda Y. Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med. 1994; 179:1041-1045.
54. Pazdrak K, Justement L, Alam R. Mechanism of inhibition of eosinophil activation by transforming growth factor-beta. Inhibition of Lyn, MAP, Jak2 kinases and STAT1 nuclear factor. J Immunol. 1995; 155:4454-4458.
55. Xie Q, Shen ZJ, Oh J, Chu H, Malter JS. Transforming growth factor-1 antagonizes interleukin-5 pro-survival signaling by activating calpain-1 in primary human eosinophils. J Clin Cell Immunol. 2011; (Suppl 1):003.
56. Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, Barnes PJ. Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol. 2000; 106:77-83.
57. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol. 1997; 158:3902-3908.
58. Hoontrakoon R, Chu HW, Gardai SJ, Wenzel SE, McDonald P, Fadok VA, et al. Interleukin-15 inhibits spontaneous apoptosis in human eosinophils via autocrine production of granulocyte macrophage-colony stimulating factor and nuclear factor-kappa B activation. Am J Respir Cell Mol Biol. 2002; 26: 404-412.
59. Wong CK, Cheung PF, Lam CW. Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation. Eur J Immunol. 2007; 37:2337-2348.
60. Temkin V, Levi-Schaffer F. Mechanism of tumour necrosis factor alpha mediated eosinophil survival. Cytokine. 2001; 15:20-26.
61. Wong CK, Hu S, Cheung PF, Lam CW. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am J Respir Cell Mol Biol. 2010; 43:305-315.
62. Coward WR, Sagara H, Wilson SJ, Holgate ST, Church MK. Allergen activates peripheral blood eosinophil nuclear factor-kappa B to generate granulocyte macrophage-colony stimulating factor, tumour necrosis factor-alpha and interleukin- 8. Clin Exp Allergy. 2004; 34:1071-1078.
63. Wong CK, Cheung PF, Ip WK, Lam CW. Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. Am J Respir Cell Mol Biol. 2007; 37:85-96.
64. Ilmarinen P, Hasala H, Sareila O, Moilanen E, Kankaanranta H. Bacterial DNA delays human eosinophil apoptosis. Pulm Pharmacol Ther. 2009; 22:167-176.
65. Ilmarinen P, Kankaanranta H. Eosinophil apoptosis as a therapeutic target in allergic asthma. Basic Clin Pharmacol Toxicol. 2014; 114(1):109-117.
66. Fujihara S, Jaffray E, Farrow SN, Rossi AG, Haslett C, Hay RT. Inhibition of NF-kappa B by a cell permeable form of I kappa B alpha induces apoptosis in eosinophils. Biochem Biophys Res Commun. 2005; 326:632-637.
67. Levi-Schaffer F, Temkin V, Malamud V, Feld S, Zilberman Y. Mast cells enhance eosinophil survival in vitro: role of TNF-alpha and granulocyte-macrophage colony-stimulating factor. J Immunol. 1998; 160:5554-5562.
68. Ochiai K, Iwamoto I, Takahashi H, Yoshida S, Tomioka H, Yoshida S. Effect of IL-4 and interferon-gamma (IFN-gamma) on IL-3- and IL-5-induced eosinophil differentiation from human cord blood mononuclear cells. Clin Exp Immunol. 1995; 99:124-128.
69. Valerius T, Repp R, Kalden JR, Platzer E. Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol. 1990; 145:2950-2958.
70. Conus S, Bruno A, Simon HU. Leptin is an eosinophil survival factor. J Allergy Clin Immunol. 2005; 116:1228-1234.
71. Bureau F, Seumois G, Jaspar F, Vanderplasschen A, Detry B, Pastoret PP, et al. CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: possible involvement in allergic inflammation. J Allergy Clin Immunol. 2002; 110:443-449.
72. Lei XF, Ohkawara Y, Stampfli MR, Mastruzzo C, Marr RA, Snider D, et al. Disruption of antigen-induced inflammatory responses in CD40 ligand knockout mice. J Clin Invest. 1998; 101:1342-1353.
73. Ilmarinen-Salo P, Moilanen E, Kinnula VL, Kankaanranta H. Nitric oxideinduced eosinophil apoptosis is dependent on mitochondrial permeability transition (mPT), JNK and oxidative stress: apoptosis is preceded but not mediated by early mPT-dependent JNK activation. Respir Res. 2012; 13:73.
74. Nopp A, Lundahl J, Stridh H. Caspase activation in the absence of mitochondrial changes in granulocyte apoptosis. Clin Exp Immunol. 2002; 128:267-274.
75. Ilmarinen-Salo P, Moilanen E, Kankaanranta H. Nitric oxide induces apoptosis in GM-CSF-treated eosinophils via caspase-6-dependent lamin and DNA fragmentation. Pulm Pharmacol Ther. 2010; 23:365-371.
76. Bailey RW, Nguyen T, Robertson L, Gibbons E, Nelson J, Christensen RE, et al. Sequence of physical changes to the cell membrane during glucocorticoidinduced apoptosis in S49 lymphoma cells. Biophys J. 2009; 96:2709-2718.
77. Wiegand UK, Corbach S, Prescott AR, Savill J, Spruce BA. The trigger to cell death determines the efficiency with which dying cells are cleared by neighbours. Cell Death Differ. 2001; 8:734-746.
78. Jessel R, Haertel S, Socaciu C, Tykhonova S, Diehl HA. Kinetics of apoptotic markers in exogeneously induced apoptosis of EL4 cells. J Cell Mol Med. 2002; 6:82-92.
79. Kenis H, van Genderen H, Deckers NM, Lux PA, Hofstra L, Narula J, et al. Annexin A5 inhibits engulfment through internalization of PS-expressing cell membrane patches. Exp Cell Res. 2006; 312:719-726.
80. Archana M, Bastian, Yogesh TL, Kumaraswamy KL. Various methods available for detection of apoptotic cells-a review. Indian J Cancer. 2013; 50:274-283.
81. Wlodkowic D, Skommer J, Darzynkiewicz Z. Cytometry of apoptosis. Historical perspective and new advances. Exp Oncol. 2012; 34:255-262.
82. Shamas-Din A, Brahmbhatt H, Leber B, Andrews DW. BH3-only proteins: orchestrators of apoptosis. Biochim Biophys Acta. 2011; 1813:508-520.
83. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010; 11:621-632.
84. Segal M, Niazi S, Simons MP, Galati SA, Zangrilli JG. Bid activation during induction of extrinsic and intrinsic apoptosis in eosinophils. Immunol Cell Biol. 2007; 85:518-524.
85. Maret M, Ruffie C, Letuve S, Phelep A, Thibaudeau O, Marchal J, et al. A role for bid in eosinophil apoptosis and in allergic airway reaction. J Immunol. 2009; 182:5740-5747.
86. Gardai SJ, Hoontrakoon R, Goddard CD, Day BJ, Chang LY, Henson PM, et al. Oxidant-mediated mitochondrial injury in eosinophil apoptosis: enhancement by glucocorticoids and inhibition by granulocyte-macrophage colony-stimulating factor. J Immunol. 2003; 170:556-566.
87. Zangrilli J, Robertson N, Shetty A, Wu J, Hastie A, Fish JE, et al. Effect of IL-5, glucocorticoid, and Fas ligation on Bcl-2 homologue expression and caspase activation in circulating human eosinophils. Clin Exp Immunol. 2000; 120:12-21.
88. Druilhe A, Arock M, Le Goff L, Pretolani M. Human eosinophils express Bcl-2 family proteins: modulation of Mcl-1 expression by IFN-gamma. Am J Respir Cell Mol Biol. 1998; 18:315-322.
89. Dewson G, Walsh GM, Wardlaw AJ. Expression of Bcl-2 and its homologues in human eosinophils. Modulation by interleukin-5. Am J Respir Cell Mol Biol. 1999; 20:720-728.
90. Sivertson KL, Seeds MC, Long DL, Peachman KK, Bass DA. The differential effect of dexamethasone on granulocyte apoptosis involves stabilization of Mcl-1L in neutrophils but not in eosinophils. Cell Immunol. 2007; 246: 34-45.
91. Vignola AM, Chanez P, Chiappara G, Siena L, Merendino A, Reina C, et al. Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol. 1999; 103:563-573.
92. Maa SH, Wang CH, Liu CY, Lin HC, Huang KH, Kuo HP. Endogenous nitric oxide downregulates the Bcl-2 expression of eosinophils through mitogen- activated protein kinase in bronchial asthma. J Allergy Clin Immunol. 2003; 112:761-767.
93. El-Gamal Y, Heshmat N, Mahran M, El-Gabbas Z. Expression of the apoptosis inhibitor bcl-2 in sputum eosinophils from children with acute asthma. Clin Exp Allergy. 2004; 34:1701-1706.
94. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87:99-163.
95. Rasola A, Bernardi P. Mitochondrial permeability transition in Ca(2+)-dependent apoptosis and necrosis. Cell Calcium. 2011; 50:222-233.
96. Letuve S, Druilhe A, Grandsaigne M, Aubier M, Pretolani M. Involvement of caspases and of mitochondria in Fas ligation-induced eosinophil apoptosis: modulation by interleukin-5 and interferon-gamma. J Leukoc Biol. 2001; 70:767-775.
97. Letuve S, Druilhe A, Grandsaigne M, Aubier M, Pretolani M. Critical role of mitochondria, but not caspases, during glucocorticosteroid-induced human eosinophil apoptosis. Am J Respir Cell Mol Biol. 2002; 26:565-571.
98. Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J Biol Chem. 2009; 284:21777-21781.
99. Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J. 2004; 384:201-232.
100. Zhang JP, Wong CK, Lam CW. Role of caspases in dexamethasone-induced apoptosis and activation of c-Jun NH2-terminal kinase and p38 mitogenactivated protein kinase in human eosinophils. Clin Exp Immunol. 2000; 122: 20-27.
101. Kankaanranta H, Ilmarinen P, Zhang X, Nissinen E, Moilanen E. Antieosinophilic activity of orazipone. Mol Pharmacol. 2006; 69:1861-1870.
102. Kankaanranta H, Janka-Junttila M, Ilmarinen-Salo P, Ito K, Jalonen U, Ito M, et al. Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils. J Inflamm (Lond). 2010; 7:9.
103. Hasala H, Giembycz MA, Janka-Junttila M, Moilanen E, Kankaanranta H. Histamine reverses IL-5-afforded human eosinophil survival by inducing apoptosis: pharmacological evidence for a novel mechanism of action of histamine. Pulm Pharmacol Ther. 2008; 21:222-233.
104. Daigle I, Simon HU. Critical role for caspases 3 and 8 in neutrophil but not eosinophil apoptosis. Int Arch Allergy Immunol. 2001; 126:147-156.
105. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases- 2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol. 1999; 144:281-292.
106. Niazi S, Robertson NM, Agrawal A, Hastie AT, Peters SP, Zangrilli J. Overlap between death receptor and non-receptor-mediated mechanisms during apoptosis in human eosinophils. Chest. 2003; 123:345S.
107. Oh J, Malter JS. Pin1-FADD interactions regulate Fas-mediated apoptosis in activated eosinophils. J Immunol. 2013; 190:4937-4945.
108. Rao L, Perez D, White E. Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol. 1996; 135:1441-1455.
109. Allsopp TE, McLuckie J, Kerr LE, Macleod M, Sharkey J, Kelly JS. Caspase 6 activity initiates caspase 3 activation in cerebellar granule cell apoptosis. Cell Death Differ. 2000; 7:984-993.
110. Ruchaud S, Korfali N, Villa P, Kottke TJ, Dingwall C, Kaufmann SH, et al. Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J. 2002; 21:1967-1977.
111. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia- Calvo M, et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem. 1997; 272:17907-17911.
112. Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer. 2011; 11:364-374.
113. Harwood SM, Yaqoob MM, Allen DA. Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis. Ann Clin Biochem. 2005; 42:415-431.
114. Kankaanranta H, Giembycz MA, Barnes PJ, Haddad el-B, Saarelainen S, Zhang X, et al. Hydrogen peroxide reverses IL-5 afforded eosinophil survival and promotes constitutive human eosinophil apoptosis. Int Arch Allergy Immunol. 2002; 127:73-78.
115. Wedi B, Straede J, Wieland B, Kapp A. Eosinophil apoptosis is mediated by stimulators of cellular oxidative metabolisms and inhibited by antioxidants: involvement of a thiol-sensitive redox regulation in eosinophil cell death. Blood. 1999; 94:2365-2373.
116. Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol. 2007; 47:143-183.
117. Martinez-Losa M, Cortijo J, Juan G, Ramon M, Sanz MJ, Morcillo EJ. Modulatory effects of N-acetyl-L-cysteine on human eosinophil apoptosis. Eur Respir J. 2007; 30:436-442.
118. Nissim Ben Efraim AH, Eliashar R, Levi-Schaffer F. Hypoxia modulates human eosinophil function. Clin Mol Allergy. 2010; 8:10.
119. Kano G, Almanan M, Bochner BS, Zimmermann N. Mechanism of siglec-8-mediated cell death in IL-5-activated eosinophils: role for reactive oxygen species- enhanced MEK/ERK activation. J Allergy Clin Immunol. 2013; 132:437-445.
120. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007; 26:3100-3112.
121. Wancket LM, Frazier WJ, Liu Y. Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci. 2012; 90:237-248.
122. Eichhorst ST, Muller M, Li-Weber M, Schulze-Bergkamen H, Angel P, Krammer PH. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol. 2000; 20:7826-7837.
123. Guan B, Yue P, Lotan R, Sun SY. Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene. 2002; 21:3121-3129.
124. Schroeter H, Boyd CS, Ahmed R, Spencer JP, Duncan RF, Rice-Evans C, et al. c-Jun N-terminal kinase (JNK)-mediated modulation of brain mitochondria function: new target proteins for JNK signalling in mitochondrion-dependent apoptosis. Biochem J. 2003; 372:359-369.
125. Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev. 2006; 70:1061-1095.
126. Hanawa N, Shinohara M, Saberi B, Gaarde WA, Han D, Kaplowitz N. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem. 2008; 283:13565-13577.
127. Lin X, Wang YJ, Li Q, Hou YY, Hong MH, Cao YL, et al. Chronic high- dose morphine treatment promotes SH-SY5Y cell apoptosis via c-Jun N-terminal kinase-mediated activation of mitochondria-dependent pathway. FEBS J. 2009; 276:2022-2036.
128. Lu C, Zhu F, Cho YY, Tang F, Zykova T, Ma WY, et al. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell. 2006; 23:121-132.
129. Hasala H, Zhang X, Saarelainen S, Moilanen E, Kankaanranta H. c-Jun N- terminal kinase mediates constitutive human eosinophil apoptosis. Pulm Pharmacol Ther. 2007; 20:580-587.
130. Wilson DJ, Fortner KA, Lynch DH, Mattingly RR, Macara IG, Posada JA, et al. JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in human T cells. Eur J Immunol. 1996; 26:989-994.
131. Cahill MA, Peter ME, Kischkel FC, Chinnaiyan AM, Dixit VM, Krammer PH, et al. CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases. Oncogene. 1996; 13:2087-2096.
132. Hebestreit H, Dibbert B, Balatti I, Braun D, Schapowal A, Blaser K, et al. Disruption of Fas receptor signaling by nitric oxide in eosinophils. J Exp Med. 1998; 187:415-425.
133. Yin H, Shi Z, Jiao S, Chen C, Wang W, Greene MI, et al. Germinal center kinases in immune regulation. Cell Mol Immunol. 2012; 9:439-445.
134. Ura S, Nishina H, Gotoh Y, Katada T. Activation of the c-Jun N-terminal kinase pathway by MST1 is essential and sufficient for the induction of chromatin condensation during apoptosis. Mol Cell Biol. 2007; 27:5514-5522.
135. De Souza PM, Kankaanranta H, Michael A, Barnes PJ, Giembycz MA, Lindsay MA. Caspase-catalyzed cleavage and activation of Mst1 correlates with eosinophil but not neutrophil apoptosis. Blood. 2002; 99:3432-3438.